Podcast by Mark Opdahl
…
continue reading
Manners Optional Podcasts
Ekse Shap Fede! Welcome to a podcast by Thato Rampedi a popular South African YouTuber. Thato runs multiple segements on his channel including coversations and has decided to create long formed content based on his upbringing, experiences and life journeys. His podcast aims to entertain and educate in a light hearted manner. He has two co-hosts who are his best friends Tladi and Lucas who will be joining him on many of the episodes.
…
continue reading
Where real life, modern, todays young Christians discuss real topics in a raw, uncensored manner. The revolution :)
…
continue reading
As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoke ...
…
continue reading
Let's talk about stuff and things, and which one is better. For the past 8 years, I've been working on a hobby, thats turned into a project of passion, and then into an idea for a company. I want to give storys a new outlet, a new option for the manner in which they are delivered. It doesn't have to be so singular.
…
continue reading
Connect Our Elders believes that to appropriately care for our Nation’s Elders it is not enough to just look at things in a compartmentalized manner as issues arise.We must be proactive in educating our Elders about adequate planning as far as finances, estate planning, trusts, etc in addition to letting them know proactively about all of the various levels of care on the continuum, how they work together, how each is paid for, as well as the community resources, technology solutions, and ot ...
…
continue reading
First published anonymously due to its seditious content in 1776, the pamphlet argues for the need of American colonists to pursue complete independence from Great Britain, and not be driven simply by the urge to free themselves from unfair taxation. Paine provides argumentation for his revolutionary ideas, suggesting the unification of colonial forces to achieve this goal. Furthermore, Paine strengthens his case by clearly asserting the advantages that would come out as a result of independ ...
…
continue reading
Welcome to the F Sharp Podcast Presented by Harmoney Wealth PLLC - a podcast geared to educate you on all things financial. Co-hosts Tanner Bortnem and Adam Henning discuss various financial topics presented in a consumable and entertaining manner. Tanner is a CERTIFIED FINANCIAL PLANNER™ professional, JD and financial expert, while Adam is a marketing professional and small business owner. This podcast is for informational and entertainment purposes only, and should not be relied upon as a ...
…
continue reading
This show speaks about finding & keeping love in your personal & professional life. Loving who we are, having loving relationships and loving what we do for a living are essential ingredients to experiencing a happy and successful life. How we achieve that is told in examples through interviews with others who have struggled with life's biggest questions. We also hear about the host's experiences over the course of more than 20 years helping others in transition after an involuntary job loss ...
…
continue reading
In this podcast we talk about what discipleship looks like in the 21st Century and how we can be more effective discipling this generation so they can disciple the next generation of followers of Christ.
…
continue reading
1
2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA ...
7:41
7:41
Play later
Play later
Lists
Like
Liked
7:412025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings An interview with: Aditya Bardia MD MPH, Professor of Medicine and Director of Translational Research Integration, U…
…
continue reading
1
ASH 2025 Orlando: Childhood Leukemia Cured But Families Broke! “Financial Toxicity” is Often More Worrying than your Child’s Cancer
ASH 2025 Orlando: Childhood Leukemia Cured But Families Broke. “Financial Toxicity” is Often More Worrying than you Child’s Cancer An interview with: Daniel Zheng, Instructor, Children’s Hospital of Philadelphia, Attending Oncologist, Division of Oncology, Philadelphia PA, United States ORLANDO, USA—Although most children with acute lymphoblastic l…
…
continue reading
1
ASH 2025, Orlando: Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies
33:51
33:51
Play later
Play later
Lists
Like
Liked
33:51https://www.audiomedica.com/wp-content/2025/12/251209-0900-Peihua-Lu-Robert-Chiesa-C2998-Discussion-at-ASH-AJO-PRODUCTION-MASTER.mp3Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies A discussion interview with Peihua Lu MD from Lu Daopei Hospital in Beijing, Chin…
…
continue reading
1
Stop Making a Making Problem's Your Salary's Problems (Financial Education YOU NEED)
1:01:44
1:01:44
Play later
Play later
Lists
Like
Liked
1:01:44Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
STOP Being Your Partner's EVERYTHING | Why You Stayed Too Long
47:48
47:48
Play later
Play later
Lists
Like
Liked
47:48Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Sober Living in Joburg: Why My Friends Stopped Inviting Me Out
1:03:14
1:03:14
Play later
Play later
Lists
Like
Liked
1:03:14Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Balancing Faith, Finances & Fitness | The Real Self-Mastery Talk
52:20
52:20
Play later
Play later
Lists
Like
Liked
52:20Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Why So Many of Us Fear Failure and How to Break Free from It | Failure & Why Giving Up is no option
1:06:19
1:06:19
Play later
Play later
Lists
Like
Liked
1:06:19Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Is Your Partner a FINANCIAL RED FLAG? (Money & Relationships Exposed!)
58:28
58:28
Play later
Play later
Lists
Like
Liked
58:28Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer
An interview with Jeanne Tie MD, Medical Oncologist, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. BERLIN, Germany—Liquid biopsy as a means of monitoring disease control in patients with stage three colon cancer has been investigated in a study from Melbo…
…
continue reading
1
Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer
Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer An interview with: Paul H Cottu MD PhD, Medical Oncologist and Associate Professor, Institute Curie, Paris, France BERLIN, Germany—Patients with high-risk, hormone receptor positive, HER2 negative early breast…
…
continue reading
1
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
An interview with Li Zhang MD, Medical Oncologist and Full Professor, Sun Yat-sen University Cancer Center, Guangzhou, China BERLIN, Germany—A doubling of progression-free survival, and highly statistically significant benefit for overall survival, has been achieved in patients with epidermal growth factor- (EGFR-) mutated non-small cell lung cance…
…
continue reading
1
Erwei Song MD PhD, ESMO Berlin: Antibody Drug Conjugate Trastuzumab Resetecan Brings Early Significant Progression Free Survival Benefit in Patients with Previously Treated HER2+ Advanced Breast Cancer ...
An interview with: https://www.audiomedica.com/wp-content/2025/11/251019-Erwei-Song-ESMO-2025-PRODUCTION-MASTER.mp3, Director of Health Science Center, President, Sun Yat-sen Memorial Hospital, Guangzhou (SYSU), Guangzhou, China. BERLIN, Germany—The open-label HORIZON-Breast01 phase-three study has reported early data showing that, for previously t…
…
continue reading
1
Andrew Clamp MD, PhD, ESMO Berlin: Weekly Dose-Dose Chemotherapy Brings Big Survival Benefit for Patients with High-Risk Ovarian Cancer
0:07
0:07
Play later
Play later
Lists
Like
Liked
0:07An interview with: Andrew Clamp MD, PhD, Consultant Medical Oncologist, Christie Hospital, Manchester, UK BERLIN, Germany—An important therapeutic gain in terms of overall- and progression-free survival has been achieved merely by changing the chemotherapy dose schedule given to patients with high-risk stage three or four epithelial ovarian cancer.…
…
continue reading
1
Nima Nabavizadeh MD; ESMO Berlin: Multi-Cancer Early Detection Test: PATHFINDER II study Finds Early Promise
An interview with Nima Nabavizadeh MD, Associate Professor of Radiation Medicine, Oregon Health & Science University (OHSU), Portland, USA, Chief Medical Officer, Cancer Early Detection Research Center, Portland, Oregon.https://www.audiomedica.com/wp-content/2025/11/251107-Nima-Nabavizadeh-MD-ESMO-2024-PRODUCTION-MASTER.mp3 BERLIN, Germany—A pan-ca…
…
continue reading
1
The Broke Boyfriend Is A Disease: How Financial Lack Kills Relationships
56:55
56:55
Play later
Play later
Lists
Like
Liked
56:55Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Xiuning Le MD PhD; ESMO 2025: Sevabertinib Success for Patients with HER2-Mutated Non-Small Cell Lung Cancer in SOHO-01 Study
An interview with: Xiuning Le MD PhD, Medical Oncologist, Department of Thoracic Medicine, UT MD Anderson Cancer Center, Houston TX BERLIN, Germany—Mutations in the HER2 molecule can be found in a few per cent of non-small cell lung cancers, and these can now be targeted by the new drug sevabertinib that can bring benefit to patients who have the m…
…
continue reading
1
ESMO 2025; Christof Vulsteke MD PhD: Perioperative Enfortumab Vedotin Therapy With Pembrolizumab Boosts Event-Free and Overall Survival in Platinum-Ineligible Patients with Muscle-Invasive Bladder Cancer ...
0:07
0:07
Play later
Play later
Lists
Like
Liked
0:07An interview with: Christof Vulsteke MD PhD, Medical Oncologist, Head of the Integrated Cancer Center Ghent, Belgium BERLIN, Germany—Patients with muscle invasive bladder who were ineligible for cisplatin chemotherapy gained large, clinically meaningful and statistically significant benefits from treatment with the antibody drug conjugate enfortuma…
…
continue reading
1
Your "Loyal" Friends Are Holding You Back | Outgrowing Your Circle for Success
38:02
38:02
Play later
Play later
Lists
Like
Liked
38:02Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Xichun Hu MD PhD; ESMO 2025: Antibody Drug Conjugate Trastuzumab Botidotin Outperforms Trastuzumab Emtansine in Patients with HER2-Positive Unresectable or Metastatic Breast Cancer
An interview with: Xichun Hu MD PhD, Professor, Director, Department of Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China BERLIN, Germany—In a head-to-head comparison of two antibody drug conjugates used to treat unresectable or metastatic breast cancer, patients treated with trastuzumab botidotin lived more than twice as …
…
continue reading
1
Martin Wermke MD; ESMO 2025: Initial Therapy with Bi-Specific T-cell Engager Tarlatamab Promises Better Outcomes in Patients with Small Cell Lung Cancer
An interview with: Martin Wermke MD, TU Dresden, NCT/UCC Early Clinical Trial Unit and Medical Clinic, Poliklinik I, Natural Centre for Tumor Diseases, Dresden, Germany BERLIN, Germany—The prospect of markedly better outcomes for patients with small cell lung cancer, with “encouraging initial survival outcomes”, was raised by findings from the DeLL…
…
continue reading
1
John P. Crown MD MBA: ESMO 2025, Berlin: Adjuvant Ribociclib Brought Longer Freedom from Metastases for Patients with HR+/HER2- Early Breast Cancer: NATALEE Five Year Outcomes
An interview with: John P. Crown MD MBA, Consultant Medical Oncologist, St. Vincent’s University Hospital, Dublin, Professor of Translational Cancer Research, Dublin City University, Professor of Medicine, University College Dublin Ireland. BERLIN, Germany—Patients with high-risk node-negative ER-positive HER2-negative early breast cancer who had t…
…
continue reading
1
Javier C Cortés MD PhD: ESMO 2025, Berlin: Initial Therapy with Sacituzumab Govitecan Improves Progression-Free Survival in Patients with Newly-Diagnosed Metastatic Triple Negative Breast Cancer—ASCENT ...
An interview with: Javier C Cortés MD PhD, Breast Cancer Medical Oncologist, IOB Madrid, Institute of Oncology, Madrid, and International Breast Cancer Centre, Barcelona, Spain BERLIN, Germany—Treatment with the antibody drug conjugate (ADC) sacituzumab govitecan (that targets the Trop-2 cancer-associated protein, delivering a cytotoxic topoisomera…
…
continue reading
1
Trevor Leong MD: Operable Gastric or GE-Junction Adenocarcinoma: No Advantage from Neoadjuvant Radiotherapy
An interview with: Trevor Leong MD, Peter McCallum Cancer Centre, Radiation Oncology Department, Melbourne, Australia BARCELONA, Spain—Although pre-operative radiotherapy brought better response rates in patients resected for their gastric or GE-junction adenocarcinomas, there was no improvement in survival. This is the clear finding from a big, lo…
…
continue reading
1
Domenica Lorusso MD PhD: Adding Early PD-1 Checkpoint Inhibition brings Big Reduction of Deaths for Patients with Newly Diagnosed Locally Advanced High-Risk Cervix Cancer
7:20
7:20
Play later
Play later
Lists
Like
Liked
7:20By Audio Medica News
…
continue reading
1
James Larkin FRCP, PhD: CheckMate 067 Study 10-Year Data Show Advanced Melanoma Landscape Transformed by Combo Checkpoint Inhibitor Therapy
14:58
14:58
Play later
Play later
Lists
Like
Liked
14:58An interview with: James Larkin FRCP, PhD, Medical Oncologist, Professor, Royal Marsden Hospital, London Checkpoint inhibitor therapy for advanced melanoma has achieved sustained responses and long-term overall survival, transforming the prognosis for as many as half of all patients. 10-year survival outcomes from the phase Ill CheckMate 067 trial …
…
continue reading
1
Why Do We Settle For Intimacy But Struggle With Connection
56:03
56:03
Play later
Play later
Lists
Like
Liked
56:03Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
6:07
6:07
Play later
Play later
Lists
Like
Liked
6:07An interview with: Jefferson DeKloe BSc, Department of Otolaryngology, Thomas Jefferson University, Philadelphia, PA CHICAGO, USA—Although the take-up of vaccination for human papilloma virus (HPV) among girls and boys in the USA has been lower than in many other industrial countries, American researchers have now shown clearly that in addition to …
…
continue reading
1
Rebecca Dent MD: ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……
13:13
13:13
Play later
Play later
Lists
Like
Liked
13:13An interview with Rebecca Dent MD, Deputy Chief Executive Officer, National Cancer Centre, Singapore, ESMO 2024 Scientific Chair. ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……” BARCELONA, Spain—At the last Annual Meeting of the European Society for Medical O…
…
continue reading
1
Bart Neyns MD PhD: Patients with Recurrent Glioblastoma Lived Markedly Longer in Phase 1 Study of Intracranial Autologous Myeloid Dendritic Cell Therapy
10:55
10:55
Play later
Play later
Lists
Like
Liked
10:55Audio Journal of Oncology interview with: Bart Neyns MD PhD, Vrije Universiteit Brussel, Faculty of Medicine and Pharmacy, Medical Oncology Department, Brussels, Belgium BARCELONA, Spain—Intracranial administration of autologous dendritic cells was combined with combination checkpoint inhibition in a phase 1 study of patients with recurrent gliobla…
…
continue reading
1
Victor Velculescu MD PhD: Ovarian Cancer Noninvasive Detection by Circulating DNA Fragmentome and Protein Biomarker AI Analysis
13:33
13:33
Play later
Play later
Lists
Like
Liked
13:33An interview with: Victor Velculescu MD PhD, Co-director, Cancer Genetics & Epigenetics Program, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. SAN DIEGO, USA—A blood test using an artificial intelligence DNA pattern recognition system that brings earlier, more certain detection of o…
…
continue reading
1
Timothy Yap MD PhD MBBS: Selective PARP1 Inhibitor Saruparib Clinical Promise in Solid Tumors with Homologous Recombination Repair Deficiency
18:45
18:45
Play later
Play later
Lists
Like
Liked
18:45Audio Journal of Oncology: Sept 23rd, 2025 An interview with: Timothy Yap MD PhD MBBS, Professor of Investigational Cancer Therapeutics, Head of Clinical Development, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, USA SAN DIEGO, USA—Breast, ovarian, pancreatic, prostate and other solid tumors with mutations…
…
continue reading
By Sarah Barker
…
continue reading
1
Stacey Kenfield ScD and June Chan ScD: Prostate Cancer Management: New Evidence of Big Benefit from Exercise:
10:28
10:28
Play later
Play later
Lists
Like
Liked
10:28Interviews with: Stacey A. Kenfield ScD, Epidemiologist, Professor of Urology, Epidemiology and Biostatistics, and June Chan ScD, Cancer Epidemiologist, Department of Epibiostat and Urology, University of California San Francisco, California USA. SAN DIEGO, USA—Physical exercise keeps patients with prostate cancer alive longer, according to a combi…
…
continue reading
1
Jonathan T. Yang MD PhD: Radiosensitizer Shows Early Clinical Promise to Support Glioblastoma Radiotherapy
10:59
10:59
Play later
Play later
Lists
Like
Liked
10:59An interview with Jonathan T. Yang MD PhD, Washington University, Seattle, USA, (Formerly of Memorial Sloan Kettering Cancer Center, New York.) SAN DIEGO, USA—An international phase one clinical study has found that a drug known to inhibit DNA damage repair was able to boost the efficacy of radiotherapy in patients being treated for their glioblast…
…
continue reading
1
Heather McArthur MD MPH: Adjuvant Checkpoint Inhibition: Did Not Improve Survival in Patients with Triple-Negative Breast Cancer
10:06
10:06
Play later
Play later
Lists
Like
Liked
10:06An interview with: Heather McArthur MD MPH, Clinical Director Breast Cancer, Komen Distinguished Chair Clinical Breast Research, University of Texas Southwestern Medical Center, Dallas TX MILAN, Italy—Adjuvant therapy with a checkpoint inhibitor did not benefit patients with triple negative breast cancer in a big new study reported to the 14th Euro…
…
continue reading
1
Does Our Parents Advice Still Work Today?
50:37
50:37
Play later
Play later
Lists
Like
Liked
50:37Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Stefan Paepke MD: An End to “Jumping Breasts” with Mesh Supported Pre-Pectoral Breast Implants
10:48
10:48
Play later
Play later
Lists
Like
Liked
10:48An interview with: Stefan Paepke MD, Interdisciplinary Breast Centre, Technical University of Munich, Germany, recorded at the 14th European Breast Cancer Conference, Milan, Italy. MILAN, Italy—Women who need surgical implants after their mastectomy for breast cancer could now benefit from mesh-supported prosthetics that bring high rates of satisfa…
…
continue reading
1
Sophie Bosma MD PhD:“Young Boost” Trial Finds Low-Dose Radiation Boost Optimal for Young Patients with High-Risk Early Breast Cancer
8:46
8:46
Play later
Play later
Lists
Like
Liked
8:46An interview with Sophie Bosma MD PhD, from The Netherlands Cancer Institute, Amsterdam recorded at the 14th European Breast Cancer Conference in Milan. MILAN, Italy—The optimal radiation boost dose to protect young patients with early breast cancer has been investigated with ten years of follow up in the “Young Boost trial” conducted in the Nether…
…
continue reading
1
Adri Voogd PhD: Ductal Carcinoma in Situ: Good Outcomes from Breast Conserving Therapy, but Benefits, Risks, Costs Still Need to be Optimized
15:54
15:54
Play later
Play later
Lists
Like
Liked
15:54An interview with: Adri Voogd PhD, Associate Professor of Clinical Epidemiology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands MILAN, Italy—Although outcomes following breast conserving surgery (with or without radiotherapy) for ductal carcinoma in situ (DCIS) are excellent, it is still not clear …
…
continue reading
1
Annemiek van Hemert MD PhD: “Breast Cancer: MARI Node Marker Helps Most Patients with Extensive Nodal Disease Safely Avoid Axillary Lymph Node Dissection”
10:16
10:16
Play later
Play later
Lists
Like
Liked
10:16An interview with Annemiek van Hemert MD PhD, Surgical Oncology Department, Antoni van Leeuwenhoek-Netherlands Cancer Institute (AVL-NKI), Amsterdam Netherlands MILAN, Italy—Four out of five patients with extensive nodal spread of their breast cancer could be spared extensive axillary dissection, if a new method of marking lymph nodes is used. That…
…
continue reading
1
Tim Rattay MBChB PhD: Artificial Intelligence Tool Minimizes Arm Lymphedema After Breast Cancer Surgery and Radiotherapy
14:05
14:05
Play later
Play later
Lists
Like
Liked
14:05An interview with: Tim Rattay MBChB PhD, Consultant Breast Surgeon, University Hospitals of Leicester, Associate Professor in Breast Surgery, Leicester Cancer Research Centre, University of Leicester, England, UK. A report from the 14th European Breast Cancer Conference, Milan, Italy MILAN, Italy—An artificial intelligence tool can predict the risk…
…
continue reading
1
The Rise and Fall of Influencers || Why Does Everyone Want To Be An Influencer
1:02:54
1:02:54
Play later
Play later
Lists
Like
Liked
1:02:54Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Yasmin Civil MD PhD: Low-Risk ER+ Breast Cancer: ABLATIVE Trial Finds Marked Benefit from MRI-Guided Single-Dose Neoadjuvant Partial Breast Radiotherapy
9:13
9:13
Play later
Play later
Lists
Like
Liked
9:13An interview with Yasmin Civil MD PhD, UMC Hospital, Amsterdam, Netherlands. MILAN, Italy—Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil MD PhD from the UMC Hospital in Amsterdam, who reported five-year results from the ABLATIVE trial of pre-oper…
…
continue reading
1
Why Success Doesn't Guarantee Happiness (The Harsh Reality)
47:42
47:42
Play later
Play later
Lists
Like
Liked
47:42Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
The Real Reason Why Men Cheat (And It's Not What You think)
52:10
52:10
Play later
Play later
Lists
Like
Liked
52:10Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Neo-Adjuvant Pembrolizumab Improved Outcomes with High-Risk ER+ HER2- Early Breast Cancer
8:55
8:55
Play later
Play later
Lists
Like
Liked
8:55An interview with Heather McArthur MD MPH, Clinical Director of Breast Cancer, Komen Distinguished Chair in Clinical Breast Research, University of Texas Southwestern Medical Center, Dallas, USA MILAN, Italy—Patients with early breast cancer testing positive for estrogen receptor (ER+) and negative for human epidermal growth factor receptor 2 (HER2…
…
continue reading
1
Laura J. van ’t Veer PhD: Triple Negative Early Breast Cancer Genetic Sub-Types Predict No Benefit from Neoadjuvant Pembrolizumab
15:48
15:48
Play later
Play later
Lists
Like
Liked
15:48An interview with: Laura J. van ’t Veer PhD, Professor of Laboratory Medicine, Co-leader of the Breast Oncology Program, Director of Applied Genomics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco. MILAN, Italy—Around 25 per cent of patients with newly-diagnosed triple negative breast cancer will not benef…
…
continue reading
1
The Unspoken Struggle of Men: The Loneliness Trap
54:45
54:45
Play later
Play later
Lists
Like
Liked
54:45Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.comfor information about our collection and use of personal data foradvertising.By Thato Rampedi
…
continue reading
1
Érica A. Oliveira PhD: How to Overcome Drug Resistance: Patient Derived Organoids Study Finds Epigenetic Pathways in Colorectal Cancer
24:30
24:30
Play later
Play later
Lists
Like
Liked
24:30Érica A. Oliveira PhD: How to Overcome Drug Resistance: Patient Derived Organoids Study Finds Epigenetic Pathways in Colorectal Cancer Interviews with: Érica A. Oliveira PhD, Senior Scientific Officer, Genomics and Evolutionary Dynamics, Institute of Cancer Research, Sutton, London UK And: Christopher Sng MD, Clinical Research Fellow, Institute of …
…
continue reading